Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the…
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where…
Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between…
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about…
Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means…
AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms…
DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the…
A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession…
Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap…
All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.
Most investors trade in and out of healthcare stocks chasing quarterly catalysts, but a small group of retirement portfolios quietly compound decade after decade on a single holding built to survive patent…
With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.
AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate.…
JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.
